SEC Tracker
Get the app

Medline MDLN

Medline Q2 FY26: revenue $7.7B; diluted EPS $0.07

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Medline reported for Q2 FY26, the quarter ended Jun 27, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$7.7BNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS$0.07No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$2.3BNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations$715.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Medline files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Solventum SOLV public float $13.1B, Jun 30, 2025
  2. Hologic HOLX public float $13.6B, Mar 29, 2025, over 18 months old
  3. Align Technology ALGN public float $11.1B, Jun 30, 2025
  4. West Pharmaceutical Services WST public float $15.7B, Jun 30, 2025
  5. Baxter International BAX public float $16.0B, Jun 30, 2025